Aurobin ointment 20g — Made in Hungary — Free Delivery

Pharmacological properties

Pharmacodynamics. Aurobin is a combined preparation, which contains active substances in an optimal ratio that are effective in the treatment of inflammatory processes and pain localized in the perianal region. prednisolone capronate is a non-halogenated glucocorticoid with a local anti-inflammatory effect. reduces vascular permeability, increases the tone of the walls of blood vessels, reduces the severity of symptoms of inflammation. lidocaine eliminates pain and burning sensation in a short time. dexpanthenol promotes the regeneration of the affected epithelium and mucous membranes.

Pharmacokinetics. Pharmacokinetic studies have not been performed with the ointment. The active substances of the preparation have mainly local effects. When applied topically, prednisolone can be absorbed and cause systemic effects. Prednisolone is rapidly distributed in all tissues of the body. Strongly binds to blood plasma proteins. It is excreted in the urine in the form of conjugates. Prednisolone quickly crosses the placenta, enters breast milk.

Lidocaine is well absorbed from the mucous membrane and affected skin. Strongly binds to blood plasma proteins. T1 / 2 lidocaine from blood plasma - 1-2 hours. Metabolized in the liver. Impaired renal function does not affect the excretion of the parent substance, but can lead to the accumulation of its active metabolite. Penetrates through the placenta, the BBB and into breast milk.

Indications

Processes accompanied by inflammation of the perianal region: itching, eczema and dermatitis of the perianal region, hemorrhoids, cracks in the anus.

Application

For external use only.

Avoid using the ointment for a long time and on a large surface of the skin, regardless of the patient's age.

Application under an occlusive dressing is not recommended.

Adults and elderly patients. A thin layer of ointment is applied to the affected area 2–4 ​​times a day. With a decrease in the severity of symptoms, the ointment is used less often. The duration of therapy should not exceed 5-7 days.

Children. Children aged 1 year and older can use the preparation only in exceptional cases and in the minimum dose that ensures the achievement of a therapeutic effect, and no more than 2 times a day. The duration of treatment for children should not exceed 5 days.

Contraindications

Hypersensitivity (allergy) to one of the active or any of the excipients of the preparation. hypersensitivity to other local anesthetics of the amide type (for example, bupivacaine, etidocaine, mepivacaine and prilocaine). treatment of the eyes or periocular area. primary bacterial, viral, or fungal skin lesions, including herpes simplex. rosacea on the face, acne vulgaris, perioral dermatitis or diaper rash, tuberculosis of the skin, skin manifestations of syphilis, dryness, peeling of the skin. simultaneous treatment with lidocaine for other indications. skin tumors. Cushing's syndrome. vaccination period. children under the age of 1 year. i trimester of pregnancy.

Side effects

Local treatment with glucocorticoids can cause local side effects.

With prolonged topical application or application to large areas of the skin, it is possible to suppress the function of the adrenal cortex. This is especially often noted when using the ointment in children or under occlusive dressings. Protein catabolism can lead to negative nitrogen balance.

Absorption of large amounts of lidocaine after topical application can lead to stimulation and / or inhibition of central nervous system function.

Depending on the amount of glucocorticoid and lidocaine absorbed, the side effects listed below may occur.

Infections and invasions: activation of subclinical infections, masking the manifestations of infections, opportunistic infections;

from the immune system: hypersensitivity reactions;

from the endocrine system: suppression of the function of the adrenal cortex, hypercortisolism (as a manifestation of the resorptive action of prednisolone);

nutritional and metabolic disorders: hypokalemic alkalosis, sodium and fluid retention in the body, hypokalemia;

mental disorders: insomnia, mental disorders;

from the side of the central nervous system: convulsions, dizziness, headache, increased intracranial pressure;

on the part of the organ of vision: cataract (the likelihood of developing cataracts is higher in children), subcapsular cataract, exophthalmos, glaucoma, edema of the optic nerve head, corneal ulcer.

on the part of the cardiovascular system: heart failure, impaired cardiac conduction, hypertension, peripheral vasodilation;

from the digestive system: gastric bleeding, gastrointestinal bleeding, perforation of the gastrointestinal tract, esophagitis, pancreatitis, peptic ulcer;

on the part of the skin and subcutaneous tissue: dermatitis, folliculitis at the site of application, acne-type rashes (steroid acne), contact dermatitis, dryness, thinning and tenderness of the skin; erythema, rash, urticaria, hirsutism, hyperhidrosis, diaper rash, itching, skin atrophy, hypopigmentation, skin irritation, striae, telangiectasia, skin burning, purpura;

on the part of the musculoskeletal system: growth retardation, steroid myopathy, osteonecrosis, osteoporosis;

systemic disorders: slow wound healing;

laboratory parameters: increased intraocular pressure, negative nitrogen balance, slowing down reactions during skin tests.

Special instructions

If skin irritation or allergic reactions occur, the preparation should be discontinued immediately and appropriate symptomatic therapy should be started. to avoid local or general toxicity of the preparation, do not use the preparation on large affected skin surfaces, in skin folds, under an occlusive dressing and / or for a long time.

With prolonged use on the same skin surface, the preparation can cause skin atrophy, especially in young patients.

The preparation  is used with extreme caution in the presence of cataracts, diabetes mellitus, glaucoma, tuberculosis or anemia, as well as in the presence of suppression of the hypothalamic-pituitary system caused by glucocorticoids.

Use with caution in patients with severe heart failure, renal and hepatic insufficiency.

Caution is needed when treating patients with a weakened or potentially weakened immune system (including AIDS or HIV infection).

Use during pregnancy and lactation. The preparation is contraindicated in the first trimester of pregnancy. When prescribing the preparation in the II and III trimester of pregnancy, it is necessary to carefully assess the benefit / risk ratio.

Glucocorticoids and lidocaine pass into breast milk. Thus, glucocorticoids can affect the function of the neonatal adrenal cortex and cause impaired growth. Small amounts of lidocaine are found in breast milk. Despite the fact that in practice this does not pose any risk to the child, when using the preparation during breastfeeding, increased caution is required.

Children. In children under the age of 1 year, it is contraindicated to use the ointment.

The ability to influence the reaction rate when driving or working with other mechanisms. The potential effect on the ability to drive vehicles or work with other mechanisms has not been studied, but the possibility of the development of adverse reactions from the central nervous system and the organ of vision should be taken into account.

Interactions

Interaction studies with the use of aurobin ointment have not been conducted.

The preparation should not be used concomitantly with lidocaine due to other indications.

Simultaneous use with other antiarrhythmic preparations requires caution.

MAO inhibitors enhance the local analgesic effect of lidocaine.

Overdose

May manifest as local or systemic symptoms, depending on the amount of glucocorticoid and lidocaine absorbed. there is no specific antidote. supportive therapy should be carried out.

Storage conditions

At a temperature of 8-15 ° C.